Fifth Milestone Achieved by HemoShear with Novel Compounds for Second Target CHARLOTTESVILLE, Va., Sept. 21, 2022 /PRNewswire/ -- HemoShear Therapeutics, Inc., a privately held clinical stage ...

Horizon Therapeutics shares are down 50% from last year's highs. See why HZNP stock is one of the best investment opportunities in biotech today.

Amgen Inc. announced on Monday that it will acquire Horizon Therapeutics for $26 billion to further grow the company’s medical legacy. Horizon's best-selling drug is Tepezza.

The acquisition, announced in December, was seen as another move by a large pharma company to build out its rare disease pipeline. Horizon’s Tepezza, a treatment approved by the Food and Drug ...

Horizon Therapeutics stock jumped up on the news that the company is in talks to be bought out. The stock closed at $78.76 and opened the next day at $102.65, a 30% gain.

According to financial terms announced Monday, Amgen will pay $116.50 cash for each share of Horizon. That price represents a 19.7% premium to Horizon’s closing stock price on Friday and a 47.9% ...

Promising Systemic Sclerosis Pipeline Therapies such as Divozilimab, Avenciguat (BI 685509), Nintedanib, GSK2330811, ...

Enter Horizon Therapeutics, a company with a lineup of about a dozen medicines. In the second quarter, Horizon's net sales were $945 million, an 8% year-over-year increase.

Amgen will acquire Horizon Therapeutics, a biopharmaceutical company that focuses on treatments for rare autoimmune diseases, in a deal valued at $26.4 billion.

Biotechnology company Amgen has agreed to pay $27.8 billion to buy Horizon Therapeutics — throwing into question the future of Horizon’s sprawling Deerfield offices. Horizon, which is based in ...

Amgen is spending more than $26 billion to dive deeper into rare-disease treatments with the acquisition of drugmaker Horizon Therapeutics.. The biotech drug developer said Monday that it will pay ...